MiR-143 has been reported as a tumor suppressor that targets a large array of cancer-related signaling pathways [14–17], such as KRAS pathway [17], ERK signaling [14], glycolysis [12] and matrix metalloproteinases [18]. Here, KRAS is linked to neoplasm.